Traci McCarty | BioMarin Pharmaceutical, Inc. |
Jean-Jacques Bienaimé | BioMarin Pharmaceutical, Inc. |
Jeffrey Robert Ajer | BioMarin Pharmaceutical, Inc. |
Daniel K. Spiegelman | BioMarin Pharmaceutical, Inc. |
Henry J. Fuchs, M.D. | BioMarin Pharmaceutical, Inc. |
Salveen Richter | Goldman Sachs & Co. LLC |
Cory W. Kasimov | JPMorgan Securities LLC |
Christopher J. Raymond | Piper Jaffray & Co. |
Phil Nadeau | Cowen and Company |
Aspen Mori | Merrill Lynch, Pierce, Fenner & Smith, Inc. |
M. Ian Somaiya | BMO Capital Markets (United States) |
Stephen D. Willey | Stifel, Nicolaus & Co., Inc. |
Jing He | Gabelli & Company |
Vincent Chen | Sanford C. Bernstein & Co. LLC |
Kennen Mackay | RBC Capital Markets LLC |
Gena Wang | Barclays Capital, Inc. |
Good afternoon. My name is Kathleen and I will be your conference operator today. At this time I would like to welcome everyone to the Investor Update Fourth Quarter and Full Year 2017 Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session.